Mifamurtide for the treatment of osteosarcoma
| Status: |
In progress |
| Expected date of issue: |
TBC |
| Referral date: |
June 2008 |
| Wave: |
17 |
| Process: |
STA |
| Topic area:
|
NICE project team
| Executive Lead: |
Gillian Leng
|
| Technical Lead: |
Fay McCracken
|
| Communications manager: |
Laura Gibson
|
| Project manager: |
Bijal Joshi
|
Provisional schedule
| Closing date for invited submissions / evidence submission: |
23 October 2008 |
| 1st appraisal committee meeting: |
18 February 2009 |
| 2nd appraisal committee meeting |
18 March 2010 |
Consultees and Commentators
Project history
| Date |
Update |
| 18 December 2009 |
The Appraisal Committee met on 18th February 2009 to discuss the above mentioned appraisal. At that time the manufacturer of the drug, IDM Pharma, informed us that the date for the launch of this drug in the UK had not been finalised, and consequently the final price had not been formally announced. We therefore could not release the decision agreed by the Committee and the evidence documentation related to the appraisal at that time.
In June 2009 IDM Pharma Inc was acquired by Takeda Pharmaceuticals Company Group. In agreement with the NICE appraisal team, Takeda will be submitting an addendum with a new cost effectiveness analysis, including a proposed patient access scheme. Furthermore, the Evidence Review Group (School of Health & Related Research Sheffield) will critique the addendum submitted by Takeda.
In light of the above, the next Committee Meeting will be scheduled for 18th March 2010, to discuss this appraisal. The appraisal has been scheduled to produce guidance as close as possible to the anticipated launch of the product in the UK.
We will not release the decision agreed by the Committee in February 2009 because the evidence on which this decision has changed. All evidence documentation related to this appraisal will be released after the March 2010 meeting.
|
| 6 May 2009 |
Mifamurtide has now received a centralised marketing authorisation from the European Commission for the treatment of osteosarcoma.
Please note that the date this drug will be launched in the UK has not been finalised and the final price of the drug has not been formally announced by the manufacturer. Therefore, we cannot release the decision agreed by the Committee and the evidence documentation related to the appraisal at this time.
This appraisal continues to be temporarily on hold, and the website will be updated once further information is available.
|
| 5 March 2009 |
Mifamurtidehas not received a centralised marketing authorisation from the European Commission and therefore we are unable to circulate the Appraisal Consultation Document (ACD) for consultation. As a result we have also cancelled the Appraisal Committee Meeting scheduled for 22 April 2009. This appraisal is temporarily on hold, and the website will be updated once further information is available. |
|
Key documents
|
|
|
This page was last updated: 14 July 2009 |
